Kinetics of Cd2+ in plasma, liver and kidneys after single intravenous injection of Cd-metallothionein-II

Eur J Pharmacol. 1994 Apr 4;270(2-3):229-35. doi: 10.1016/0926-6917(94)90067-1.

Abstract

To explore the kinetics of Cd2+ in the body, rats received a single intravenous injection of CdCl2 or Cd-saturated metallothionein-II at 0.3 mg Cd/kg body weight. Cd2+ in the two agents was biexponentially eliminated from plasma: rapidly in the first 5 min, and gradually later. Compared with CdCl2, Cd-saturated metallothionein-II showed lower Cd2+ concentrations in plasma during the first 30 min; larger values for parameters concerning distribution of Cd2+, its total body clearance and half-life time in the beta phase. Cd2+ uptake in the liver was higher with CdCl2, and, conversely, in the kidneys it was higher with Cd-saturated metallothionein-II. In Cd-saturated metallothionein-II, the renal content of Cd2+ reached a maximum (8 micrograms Cd2+/g tissue) on day 1, gradually decreasing thereafter; there was a higher area under the Cd2+ content-time curve, and a lower mean residence time of Cd2+; the kidneys showed severe necrosis and defluxion of proximal tubular cells at days 1 and 5, although there were regenerative and reversion signs on day 5. These findings suggested that, in the case of Cd-saturated metallothionein-II, Cd2+ being taken into the cells of proximal tubules was excluded predominantly due to cellular death and the resultant defluxion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cadmium / blood
  • Cadmium / pharmacokinetics*
  • Cadmium / toxicity
  • Injections, Intravenous
  • Kidney / metabolism*
  • Kidney / pathology
  • Liver / metabolism*
  • Liver / pathology
  • Male
  • Metallothionein / administration & dosage
  • Metallothionein / pharmacokinetics*
  • Models, Biological
  • Rats
  • Rats, Sprague-Dawley

Substances

  • cadmium-binding protein
  • Cadmium
  • Metallothionein